Ä¢¹½ÊÓƵAPP

Yasir Al-Wakeel is a CEO-Partner at Ä¢¹½ÊÓƵAPP and Chief Executive Officer of . He is a seasoned biotech executive with deep experience building and leading innovative life science companies at various stages of growth.

Yasir most recently was an Entrepreneur in Residence at SR One, working with multiple startups, and served as President and CEO of a stealth genetics medicines company.

Prior to SR One, Yasir served as Chief Financial Officer and Head of Corporate Development of three public companies. Most recently, he held this role at Kronos Bio, where he made a strong early impact with the completion of $155M crossover financing, as well as the company’s $288M initial public offering. As head of business development, he also spearheaded a discovery deal with Genentech, announced in January 2023.

Previously, Yasir was Chief Financial and Strategy Officer at Neon Therapeutics since 2017, where he played a key role in the company’s public and private financings as well as its eventual sale to BioNTech. Prior to that, he was Chief Financial Officer and Head of Corporate Development at Merrimack Pharmaceuticals, where he helped shape and execute the company’s refocused business strategy, culminating in a $1 billion asset sale to Ipsen.

Earlier, Yasir served in senior roles in equity research and corporate finance at Credit Suisse, focused on the biotechnology sector. During his tenure in corporate finance, he was involved in more than $30 billion in strategic and financial transactions for the firm.

Yasir began his career as a practicing physician, holding both clinical and academic medical posts in the United Kingdom before his roles in finance and early-stage biotechnology. Yasir received his BM BCh (Doctor of Medicine and Surgery) from Oxford University and an M.A. in theology from Cambridge University.